[go: up one dir, main page]

WO2011025167A3 - Composition pharmaceutique pour la prévention ou le traitement du cancer comprenant un composé dérivé de 3-nitropyridine 2,6-substitué ou un de ses sels pharmaceutiquement acceptables - Google Patents

Composition pharmaceutique pour la prévention ou le traitement du cancer comprenant un composé dérivé de 3-nitropyridine 2,6-substitué ou un de ses sels pharmaceutiquement acceptables Download PDF

Info

Publication number
WO2011025167A3
WO2011025167A3 PCT/KR2010/005336 KR2010005336W WO2011025167A3 WO 2011025167 A3 WO2011025167 A3 WO 2011025167A3 KR 2010005336 W KR2010005336 W KR 2010005336W WO 2011025167 A3 WO2011025167 A3 WO 2011025167A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
pharmaceutical composition
treating cancer
substituted
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/005336
Other languages
English (en)
Korean (ko)
Other versions
WO2011025167A2 (fr
Inventor
한동초
권병목
윤영주
이진수
유제만
성승규
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Dong Wha Pharm Co Ltd
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Dong Wha Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB, Dong Wha Pharm Co Ltd filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Publication of WO2011025167A2 publication Critical patent/WO2011025167A2/fr
Publication of WO2011025167A3 publication Critical patent/WO2011025167A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique pour la prévention ou le traitement du cancer comprenant un composé dérivé de 3-nitropyridine 2,6-substitué ou un de ses sels pharmaceutiquement acceptables. La composition pharmaceutique de la présente invention peut être utilisée avantageusement pour le traitement du cancer et la prévention du cancer car elle inhibe efficacement la croissance des lignées cellulaires cancéreuses et l'activité du facteur de choc thermique 1.
PCT/KR2010/005336 2009-08-28 2010-08-13 Composition pharmaceutique pour la prévention ou le traitement du cancer comprenant un composé dérivé de 3-nitropyridine 2,6-substitué ou un de ses sels pharmaceutiquement acceptables Ceased WO2011025167A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090080742A KR101630432B1 (ko) 2009-08-28 2009-08-28 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용되는 염을 포함하는 암 예방 또는 치료용 약학 조성물
KR10-2009-0080742 2009-08-28

Publications (2)

Publication Number Publication Date
WO2011025167A2 WO2011025167A2 (fr) 2011-03-03
WO2011025167A3 true WO2011025167A3 (fr) 2011-06-16

Family

ID=43628541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/005336 Ceased WO2011025167A2 (fr) 2009-08-28 2010-08-13 Composition pharmaceutique pour la prévention ou le traitement du cancer comprenant un composé dérivé de 3-nitropyridine 2,6-substitué ou un de ses sels pharmaceutiquement acceptables

Country Status (2)

Country Link
KR (1) KR101630432B1 (fr)
WO (1) WO2011025167A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
US12098117B2 (en) 2018-12-11 2024-09-24 Duke University Compositions and methods for the treatment of cancer
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
AU2022253899A1 (en) 2021-04-07 2023-10-26 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
KR102738668B1 (ko) * 2022-02-25 2024-12-06 계명대학교 산학협력단 항암 활성을 갖는 신규 화합물 및 이의 용도
CN115611885B (zh) * 2022-08-29 2024-07-19 厦门大学 N-取代-5-((4-取代嘧啶-2-基)氨基)-1h-吲哚-2-甲酰胺衍生物
WO2025072751A1 (fr) 2023-09-29 2025-04-03 Battelle Memorial Institute Compositions de nanoparticules polymères pour l'expression in vivo de polypeptides
WO2025122954A1 (fr) 2023-12-08 2025-06-12 Battelle Memorial Institute Utilisation de nanostructures d'origami d'adn pour systèmes de stockage de données basés sur des informations moléculaires
CN119798223B (zh) * 2025-01-02 2025-10-24 沈阳药科大学 一种(1h-吲唑-5-基)氨基-2-吡啶衍生物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567272A (en) * 1983-09-21 1986-01-28 Rutgerswerke Aktiengesellschaft Pyrrole containing 2-aminonitropyridine derivatives
KR20090025371A (ko) * 2006-07-01 2009-03-10 메르크 파텐트 게엠베하 Ｈｓｐ90-유도 질병 치료용 인다졸 유도체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100566194B1 (ko) * 1999-12-29 2006-03-29 동화약품공업주식회사 신규의 3-니트로피리딘 유도체 및 그를 포함하는 약학적조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567272A (en) * 1983-09-21 1986-01-28 Rutgerswerke Aktiengesellschaft Pyrrole containing 2-aminonitropyridine derivatives
KR20090025371A (ko) * 2006-07-01 2009-03-10 메르크 파텐트 게엠베하 Ｈｓｐ90-유도 질병 치료용 인다졸 유도체

Also Published As

Publication number Publication date
KR101630432B1 (ko) 2016-06-15
KR20110023118A (ko) 2011-03-08
WO2011025167A2 (fr) 2011-03-03

Similar Documents

Publication Publication Date Title
WO2011025167A3 (fr) Composition pharmaceutique pour la prévention ou le traitement du cancer comprenant un composé dérivé de 3-nitropyridine 2,6-substitué ou un de ses sels pharmaceutiquement acceptables
WO2012047017A3 (fr) Dérivé 2,3-dihydro-isoindol-1-one et composition le comprenant
WO2010021680A3 (fr) Inhibiteurs de la bêta-sécrétase
TR201906936T4 (tr) Protein kinaza yönelik inhibitör aktiviteye sahip tiyenopirimidin türevleri.
WO2010108074A3 (fr) Inhibiteurs de pi3 kinase
WO2011093684A3 (fr) Dérivés thiéno[3,2-d]pyrimidines avec activité inhibitrice sur protéines kinases
TWI562992B (en) Indazole derivative, pharmaceutical composition thereof, and use thereof as inhibitors of kinase activity
WO2010088000A3 (fr) Composés antifibrotiques et leurs utilisations
MX2012000414A (es) Derivados piridin-4-ilo.
WO2011014795A3 (fr) Composés et compositions pouvant servir d'inhibiteurs de la kinase syk
WO2009071480A3 (fr) Dérivés de dihydroptéridin-6-one substitués, procédé de préparation desdits dérivés et leur utilisation en tant qu'inhibiteurs de kinase
IN2014KN00948A (fr)
SI2324008T1 (sl) 3,4-diarilpirazoli kot protein-kinazni inhibitorji
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
TW200801000A (en) Spiroindolinone derivatives
PH12012501649A1 (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
WO2012021796A8 (fr) Nouveaux dérivés de cyclosporine destinés à la prévention ou au traitement d'une infection virale
MX2011011083A (es) Compuestos heterociclicos como inhibidores de mek.
WO2011052923A3 (fr) Nouveaux composés d'indole 1,6-disubstitués utilisés en tant qu'inhibiteurs des protéines kinases
WO2010016683A3 (fr) Composition pour la prévention et le traitement de l'alopécie ou pour la pousse des cheveux
CA2881554C (fr) Methodes d'inhibition de la fascine
RU2018135973A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
MX341342B (es) Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2 -(1-hidroxi-1-metil-etil) pirimidin-5-il]-7-(tetrahidrofuran-2-il) -1h-benzimidazol-2-il]urea.
WO2009094560A3 (fr) Thiénopyranones en tant qu'inhibiteurs de kinase
EP2583962A4 (fr) Nouvelle thio-urée ou nouveau dérivé d'urée, procédé permettant leur préparation, et composition pharmaceutique destinée à prévenir ou à traiter le sida, les contenant en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10812181

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10812181

Country of ref document: EP

Kind code of ref document: A2